Urea Cycle Disorders Treatment Market to Surpass US$ 1,510.2 Million by 2027

Global Urea Cycle Disorders Treatment Market, by Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others (Low Protein Diet, Carglumic acid, etc.), By Enzyme Deficiency Type (OTC – Ornithine Transcarbamylase, AS – Argininosuccinate Synthetase (citrullinemia), AG – Arginase, AL – Argininosuccinate Lyase, CPS1 – Carbamoyl Phosphate Synthase, and NAGS – N-acetylglutamate Synthase), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,188.9 million in 2020 and is expected to exhibit a CAGR of 3.5% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.

The increasing number of pipeline products for the treatment of urea cycle disorders is expected to fuel growth of the global urea cycle disorders treatment market in the near future.

For instance, in September 17, 2019, Kaleido Biosciences, a clinical-stage healthcare company, initiated phase 2 clinical trial study to evaluate the efficacy and safety of KB195 in subjects with urea cycle disorder with severe symptoms. The study is estimated to be completed on November 2021.

Global Urea Cycle Disorders Treatment Market – Impact of Coronavirus (COVID-19)

• The COVID-19 pandemic caused major disruptions in the execution of clinical trials in the U.S., impacting key stakeholders across the urea cycle disorder treatment drugs market. During the pandemic, investigative site capabilities experienced upheaval, which was driven by staff furloughs, social-distancing protocols, financial losses, and concerns over patient safety. Sponsors, CROs, and other organizations that support drug development shifted to remote working environments. An estimated 80% of non-COVID-19 trials were stopped or interrupted as a result of the COVID-19 pandemic.
• An April 2020 study suggested that investigative sites demonstrated flexibility and ingenuity in adopting new approaches in order to cope with challenges presented by the COVID, with over half of investigative sites transitioning to virtual approaches to interact with their patients. A few follow-up studies were performed on COVID-19, in August 2020 has identified persistent impact of COVID on clinical trials, over 60% reported of an average or greater level of impact of COVID on the ongoing clinical trials as well as in the initiation of new trials. Respondents specifically highlighted the challenges in patient enrollment and recruitment due to the COVID-19 pandemic.
• Recently, the U.S. FDA guidance (March 2020 and updated July 2020) acknowledged that the impact of COVID-19 may require companies conducting clinical trials to consider virtual patient visits. Therefore, now there are more opportunities for using remote healthcare including conducting virtual or decentralized trials, site-less clinical trials, and use of other non-traditional approaches that do not involve in-person visits.
• Moreover, various research institutes are focusing on understanding the impact of COVID-19 on patients suffering from inherited metabolic diseases (IMD) such as urea cycle disorder. For instance, in January 2021, University Hospital, Lille, initiated an observational study on the impact of COVID-19 on the equilibrium of hereditary metabolic disease in patients with COVID-19 infection. The study is estimated to be completed by January 2023.

Browse 72 Market Data Tables and 48 Figures spread through 272 Pages and in-depth TOC on “Global Urea Cycle Disorders Treatment Market,  by Treatment Type (Amino Acid Supplements, Sodium Phenylbutyrate, Glycerol Phenylbutyrate, Sodium Benzoate, and Others (Low Protein Diet, Carglumic acid, etc.)), By Enzyme Deficiency Type (OTC – Ornithine Transcarbamylase, AS – Argininosuccinate Synthetase (citrullinemia), AG – Arginase, AL – Argininosuccinate Lyase, CPS1 – Carbamoyl Phosphate Synthase, and NAGS – N-acetyl glutamate Synthase), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)”

To know the latest trends and insights prevalent in the global Urea Cycle Disorders Treatment market, click the link below:

https://www.coherentmarketinsights.com/market-insight/urea-cycle-disorder-treatment-market-4441

Urea cycle disorders treatment market is expected to offer lucrative opportunity in the near future owing to the focus of major market players on inorganic growth strategies such as acquisitions, partnerships, and agreements to strengthen product portfolio and presence in the global market

For instance, in January 2021, Acer Therapeutics and RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company, entered into collaboration and license agreement for the worldwide development and commercialization of acer-001, a sodium Phenylbutyrate drug conjugate for the treatment of urea cycle disorders.

Key Takeaways of the Global Urea Cycle Disorders Treatment Market:

• The global Urea cycle disorders treatment market is expected to exhibit a CAGR of 3.5% during the forecast period, owing to key companies focusing on research and development for the treatment of cancer
• Among Treatment Type, Sodium Phenylbutyrate segment is estimated to hold major market share in the global urea cycle disorders treatment market during the forecast period, owing to various companies focusing on research and development of urea cycle disorders treatment
• Among enzyme deficiency type, OTC – Ornithine Transcarbamylase segment is estimated to hold major market share in the global urea cycle disorders treatment market during the forecast period, owing to various key players focusing on research and development for the treatment of OTC – Ornithine Transcarbamylase deficiency
• Among route of administration type, oral segment is estimated to hold major market share in the global urea cycle disorders treatment market during the forecast period, owing to major players focusing on research and development of orally administered drugs such as (Glycerol Phenylbutyrate) for treatment of urea cycle disorders
• Among Distribution Channel, Hospital pharmacies segment is estimated to hold major market share in the global urea cycle disorders treatment market during the forecast period, owing to major players focusing on conducting special awareness programs and financial assistance programs for treatment of urea cycle disorders through healthcare facilities
• Key players operating in the global urea cycle disorders treatment market include Bausch Health Companies, Inc., Recordati Rare Diseases Inc., Lucane Pharma SA, Acer Therapeutics, Ultragenyx Pharmaceutical Inc., Aeglea BioTherapeutics, Arcturus Therapeutics Holdings Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc., Abbott Laboratories, NESTLÉ S.A., DANONE S.A., and Mead Johnson & Company, LLC.